CXCR4 and neoplasm: Moreover, the intravenous administration of T22-DITOX-H6, following a repeated dose schedule, in a highly metastatic CXCR4+ EC mouse model, previously developed by our group, yielded a dramatic decrease in overall tumor burden and potent blockade of dissemination of peritoneal, liver and lung metastasis, in the absence of off-target or on-target systemic toxicity.